Use of lithium and cancer risk in patients with bipolar disorder: Population-based cohort study

British Journal of Psychiatry

Volumn 209, Issue 5, 2016, Pages 393-399

  Huang, Ru Yu ^a   Hsieh, Kun Pin ^b   Huang, Wan Wen ^a   Yang, Yi Hsin ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM; LITHIUM DERIVATIVE; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; BONE CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK REDUCTION; SKIN CANCER; SOFT TISSUE CANCER; UROGENITAL TRACT CANCER; ADOLESCENT; AGED; MIDDLE AGED; NEOPLASMS; REGISTER; RISK; STATISTICS AND NUMERICAL DATA; TAIWAN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK; TAIWAN; YOUNG ADULT;

EID: 84996564240     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.116181362     Document Type: Article

References (31)

1. Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 2013; 86: 191-9.
2. McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Basecke J, et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014; 54: 176-96.
3. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 2014; 5: 2881-911.
4. Brown KM, Tracy DK. Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol 2013; 3: 163-76.
5. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014; 2: 1-17.
6. Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 1998; 15: 32-6.
7. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236-42.
8. National Health Insurance Research Database, Taiwan. Data Subset. NHIRD, 2015 (http://nhird.nhri.org.tw/en/Data-Subsets.html).
9. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-9). WHO, 1978.
10. Young LT. What exactly is a mood stabilizer? J Psychiatry Neurosci 2004; 29: 87-8.
11. Bowden CL. Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 2009; 11: 20-33.
12. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2015. WHOCC, 2015 (http://www.whocc.no/atc-ddd-index/).
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
14. Gerhard T, Devanand DP, Huang C, Crystal S, Olfson M. Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry 2015; 207: 46-51.
15. Pottegard A, Friis S, Andersen M, Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol 2013; 75: 1356-64.
16. Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013; 6: 604-11.
17. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 2013; 32: 2837-49.
18. Kaae J, Carstensen L, Wohlfahrt J, Melbye M, Boyd HA. Epilepsy, antiepileptic medication use and risk of cancer. Int J Cancer 2014; 134: 932-8.
19. Singh G, Bell GS, Driever PH, Sander JW. Cancer risk in people with epilepsy using valproate-sodium. Acta Neurol Scand 2012; 125: 234-40.
20. Hallas J, Friis S, Bjerrum L, Stovring H, Narverud SF, Heyerdahl T, et al. Cancer risk in long-term users of valproate: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1714-9.
21. Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, et al. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer 2014; 120: 1394-400.
22. Boursi B, Lurie I, Mamtani R, Haynes K, Yang YX. Anti-depressant therapy and cancer risk: a nested case-control study. Eur Neuropsychopharmacol 2015; 25: 1147-57.
23. Lee HK, Eom CS, Kwon YM, Ahn JS, Kim S, Park SM. Meta-analysis: selective serotonin reuptake inhibitors and colon cancer. Eur J Gastroenterol Hepatol 2012; 24: 1153-7.
24. Walker AJ, Card T, Bates TE, Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer 2011; 104: 193-7.
25. Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, et al. Antipsychotic drugs: pro-cancer or anti-cancer? A systematic review. Med Hypotheses 2012; 79: 38-42.
26. Lin GM, Chen YJ, Kuo DJ, Jaiteh LE, Wu YC, Lo TS, et al. Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997-2009. Schizophr Bull 2013; 39: 407-16.
27. Hung Y-N, Yang S-Y, Huang M-C, Lung F-W, Lin S-K, Chen K-Y, et al. Cancer incidence in people with affective disorder: nationwide cohort study in Taiwan, 1997-2010. Br J Psychiatry 2014; 205: 183-8.
28. Health Promotion Administration, Ministry of Health and Welfare. Cancer Registry Annual Report 2010, Taiwan. Health Promotion Administration, Ministry of Health and Welfare, 2010 (http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No = 200911300001).
29. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013; 14: 154-219.
30. Bai YM, Chang CJ, Tsai SY, Chen YC, Hsiao MC, Li CT, et al. Taiwan consensus of pharmacological treatment for bipolar disorder. J Chin Med Assoc 2013; 76: 547-56.
31. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007; 31: 920-31.